This webinar will share information on the influence of multimillion-dollar pharmaceutical costs, along with successful cost containment practices demonstrated through case studies of effective intervention.

Most U.S. consumers are very interested in receiving regular messages from their health plans – if those messages are highly relevant to them and can help them stay healthier and/or save money. That’s the conclusion drawn from a new online Pollfish survey of 400 consumers conducted on behalf of RxEOB who are members of commercial and government-sponsored health plans.

A mutual health aid plan launched by Ant Financial Services Group – the dominant fintech player in China – has amassed more than 50 million users and is aiming for 300 million within two years, the company said.

Although biosimilars have not had the immediate uptake in the United States that they have had in Europe, health plans expect these products will become a staple of therapy for some diseases by 2020 – if the price is right.

EVERSANA unveiled Health Strategies Insights by EVERSANA, a comprehensive market access research and insights portfolio to help life science innovators make more informed decisions.

Denmark’s Novo Nordisk will cut around 250 jobs in the United States, but the drugmaker will also hire an as-yet undetermined number of staff to new positions.

A recently adopted tactic by U.S. health plans to limit the financial assistance drugmakers provide directly to consumers for prescription medicines is taking a toll on drug prices, according to a new analysis.

A very high percentage of Prior Authorization (PA) requests are approved…but about 40% of these prescriptions are abandoned during the PA process, around 74.4 million prescriptions a year.

Anthem Inc. is committed to supporting policy changes that help reduce, prevent and deter opioid use disorder, as well as those that help consumers better access treatment. As part of that commitment, its affiliated health plans just reached the company’s collective goal of reducing prescribed opioids filled at pharmacies by 30 percent during the past five years.

Most health plans are covering at least one of the two biosimilar products currently on the market, according to new research by the strategic advisory company Avalere.